Global Bioengineered Protein Drugs Market by Drug Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), Disease (Arthritis, Autoimmune Disorders, Blood Disorders), End-User - Forecast 2024-2030- Product Image

Sale

Global Bioengineered Protein Drugs Market by Drug Type (Monoclonal Antibodies, Therapeutic Proteins, Vaccines), Disease (Arthritis, Autoimmune Disorders, Blood Disorders), End-User - Forecast 2024-2030

Report
190 Pages
March 2024
Region: Global
360iResearch™
ID: 5887614

UP TO €844EUR$875USD£724GBP OFF until Dec 31^st 2024

The Bioengineered Protein Drugs Market size was estimated at USD 387.03 billion in 2023, USD 415.13 billion in 2024, and is expected to grow at a CAGR of 7.76% to reach USD 653.35 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Bioengineered Protein Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Bioengineered Protein Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Bioengineered Protein Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Ambrx, Inc., AMGEN INC., Aravive, Inc., Astrazeneca PLC, Baxter Healthcare, Bayer Pharmaceuticals, BRISTOL-MYERS SQUIBB, CSL LTD., F. HOFFMANN-LA ROCHE AG, GLAXOSMITHKLINE PLC, GRIFOLS S.A., Hoffman-la-Roche, MERCK & CO., INC., NOVARTIS AG, NOVO NORDISK A/S, PFIZER INC., Polaris Group, REGENERON PHARMACEUTICALS INC., SANOFI, and TAKEDA PHARMACEUTICAL CO., LTD.

Market Segmentation & Coverage

This research report categorizes the Bioengineered Protein Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Drug Type
- Monoclonal Antibodies
- Therapeutic Proteins
- Vaccines
Disease
- Arthritis
- Autoimmune Disorders
- Blood Disorders
- Cancer
- Congenital Diseases
- Heart Diseases
- Infectious Diseases
- Neurodegenerative Diseases
- Respiratory Diseases
- Skin Diseases
End-User
- CROs
- Pharmaceutical and Biotechnology Companies
- Research institutes

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

What is the market size and forecast of the Bioengineered Protein Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Bioengineered Protein Drugs Market?
What are the technology trends and regulatory frameworks in the Bioengineered Protein Drugs Market?
What is the market share of the leading vendors in the Bioengineered Protein Drugs Market?
Which modes and strategic moves are suitable for entering the Bioengineered Protein Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Bioengineered Protein Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of chronic diseases among population
5.1.1.2. Growing healthcare awareness and significant benefits of bioengineered protein drugs
5.1.1.3. Increase in healthcare spending across economies
5.1.2. Restraints
5.1.2.1. High costs associated with the bioengineered protein drugs
5.1.3. Opportunities
5.1.3.1. Growing research activities to develop and introduce novel bioengineered protein drugs
5.1.3.2. Emerging applications of nanotechnology in macromolecules delivery
5.1.4. Challenges
5.1.4.1. Stringent and time consuming approval processes
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Bioengineered Protein Drugs Market, by Drug Type

6.1. Introduction
6.2. Monoclonal Antibodies
6.3. Therapeutic Proteins
6.4. Vaccines

7. Bioengineered Protein Drugs Market, by Disease

7.1. Introduction
7.2. Arthritis
7.3. Autoimmune Disorders
7.4. Blood Disorders
7.5. Cancer
7.6. Congenital Diseases
7.7. Heart Diseases
7.8. Infectious Diseases
7.9. Neurodegenerative Diseases
7.10. Respiratory Diseases
7.11. Skin Diseases

8. Bioengineered Protein Drugs Market, by End-User

8.1. Introduction
8.2. CROs
8.3. Pharmaceutical and Biotechnology Companies
8.4. Research institutes

9. Americas Bioengineered Protein Drugs Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Bioengineered Protein Drugs Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Bioengineered Protein Drugs Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

13.1. Key Company Profiles
13.1.1. Abbott Laboratories
13.1.2. Ambrx, Inc.
13.1.3. AMGEN INC.
13.1.4. Aravive, Inc.
13.1.5. Astrazeneca PLC
13.1.6. Baxter Healthcare
13.1.7. Bayer Pharmaceuticals
13.1.8. BRISTOL-MYERS SQUIBB
13.1.9. CSL LTD.
13.1.10. F. HOFFMANN-LA ROCHE AG
13.1.11. GLAXOSMITHKLINE PLC
13.1.12. GRIFOLS S.A.
13.1.13. Hoffman-la-Roche
13.1.14. MERCK & CO., INC.
13.1.15. NOVARTIS AG
13.1.16. NOVO NORDISK A/S
13.1.17. PFIZER INC.
13.1.18. Polaris Group
13.1.19. REGENERON PHARMACEUTICALS INC.
13.1.20. SANOFI
13.1.21. TAKEDA PHARMACEUTICAL CO., LTD.
13.2. Key Product Portfolio

14. Appendix

14.1. Discussion Guide
14.2. License & Pricing

List of Figures

FIGURE 1. BIOENGINEERED PROTEIN DRUGS MARKET RESEARCH PROCESS
FIGURE 2. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2023 VS 2030
FIGURE 3. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. BIOENGINEERED PROTEIN DRUGS MARKET DYNAMICS
FIGURE 7. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
FIGURE 8. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
FIGURE 10. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 12. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. BIOENGINEERED PROTEIN DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 6. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY THERAPEUTIC PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 10. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY AUTOIMMUNE DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CONGENITAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY HEART DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY NEURODEGENERATIVE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY SKIN DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 21. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY CROS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 34. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 35. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 36. CANADA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 37. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 38. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 39. MEXICO BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 44. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 45. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 46. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 48. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 49. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 50. AUSTRALIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 52. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 53. CHINA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 54. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 55. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 56. INDIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 58. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 59. INDONESIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 60. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 61. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 62. JAPAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 64. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 65. MALAYSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 66. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 67. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 68. PHILIPPINES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 70. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 71. SINGAPORE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 72. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 73. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 74. SOUTH KOREA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 76. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 77. TAIWAN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 80. THAILAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 82. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 83. VIETNAM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 84. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 85. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 86. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 87. EUROPE, MIDDLE EAST & AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 88. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 89. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 90. DENMARK BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 91. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 93. EGYPT BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 94. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 95. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 96. FINLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 97. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 98. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 99. FRANCE BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 100. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 101. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 102. GERMANY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 104. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 105. ISRAEL BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 106. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 107. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 108. ITALY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 109. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 110. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 111. NETHERLANDS BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 112. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 113. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 114. NIGERIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 115. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 116. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 117. NORWAY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 119. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 120. POLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 121. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 122. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 123. QATAR BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 125. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 126. RUSSIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 127. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 128. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 129. SAUDI ARABIA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 130. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 132. SOUTH AFRICA BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 134. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 135. SPAIN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 136. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 137. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 138. SWEDEN BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 140. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 141. SWITZERLAND BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 142. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 143. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 144. TURKEY BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 145. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 146. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 147. UNITED ARAB EMIRATES BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 148. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 149. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
TABLE 150. UNITED KINGDOM BIOENGINEERED PROTEIN DRUGS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. BIOENGINEERED PROTEIN DRUGS MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 152. BIOENGINEERED PROTEIN DRUGS MARKET SHARE, BY KEY PLAYER, 2023
TABLE 153. BIOENGINEERED PROTEIN DRUGS MARKET LICENSE & PRICING

Companies Mentioned

Abbott Laboratories
Ambrx, Inc.
AMGEN INC.
Aravive, Inc.
Astrazeneca PLC
Baxter Healthcare
Bayer Pharmaceuticals
BRISTOL-MYERS SQUIBB
CSL LTD.
F. HOFFMANN-LA ROCHE AG
GLAXOSMITHKLINE PLC
GRIFOLS S.A.
Hoffman-la-Roche
MERCK & CO., INC.
NOVARTIS AG
NOVO NORDISK A/S
PFIZER INC.
Polaris Group
REGENERON PHARMACEUTICALS INC.
SANOFI
TAKEDA PHARMACEUTICAL CO., LTD.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	190
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 415.13 Billion
Forecasted Market Value ( USD ) by 2030	$ 653.35 Billion
Compound Annual Growth Rate	7.7%
Regions Covered	Global
No. of Companies Mentioned	21

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3257EUR$3,374USD£2,794GBP €3619EUR$3,749USD£3,104GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4125EUR$4,274USD£3,539GBP €4584EUR$4,749USD£3,932GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€4994EUR$5,174USD£4,284GBP €5549EUR$5,749USD£4,760GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5863EUR$6,074USD£5,029GBP €6514EUR$6,749USD£5,588GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7600EUR$7,874USD£6,519GBP €8445EUR$8,749USD£7,244GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects

The report addresses key questions such as

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Bioengineered Protein Drugs Global Market Report 2024

Bioengineered Protein Drugs: Global Strategic Business Report

Bioengineered Protein Drugs Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology

Global Biosimilar Monoclonal Antibodies Market by Drug Class (Abciximab, Adalimumab, Bevacizumab), Application (Diagnostic, Protein Purification, Therapeutic) - Forecast 2024-2030

Global Protein Therapeutics Market by Protein Function (Enzymatic & Regulatory, Protein Diagnostics, Vaccines), Product Type (Blood Clotting Factor, Erythropoietin, Follicle Stimulating Hormone) - Forecast 2024-2030